|Bid||42.610 x 1300|
|Ask||42.620 x 2100|
|Day's Range||42.370 - 42.820|
|52 Week Range||37.200 - 45.580|
|PE Ratio (TTM)||48.03|
|Dividend & Yield||1.95 (4.60%)|
|1y Target Est||N/A|
Emergent's shares inched up post announcement of its deal inked with GlaxoSmithKline to acquire the latter's anthrax monoclonal antibody raxibacumab.
Loup Ventures has compiled a portfolio of 17 publicly traded non-tech companies that are making investments in artificial intelligence to improve their businesses.
Gaithersburg-based Emergent BioSolutions has been on a bit of a buying spree lately. On Wednesday, the company announced it would acquire a drug for treating inhaled anthrax from pharmaceutical giant GlaxoSmithKline in an all-cash deal worth up to $96 million. The deal came less than a week after Emergent (EBS) announced it would buy French pharmaceutical giant Sanofi's smallpox vaccine business in an all-cash deal worth up to $125 million.